Fusafungine

Fusafungine
Clinical data
Other names	Fusafungin
AHFS/Drugs.com	International Drug Names
ATC code	R02AB03 (WHO) ;
Identifiers
	IUPAC name cyclo[N-oxa-DL-valyl-N-methyl-L-valyl-N-oxa-DL-valyl-N-methyl-L-valyl-N-oxa-DL-valyl-N-methyl-L-valyl];
CAS Number	1393-87-9 ;
PubChem CID	3084092;
DrugBank	DB08965 ;
UNII	65DD690W0C;
KEGG	D08002 ;
CompTox Dashboard (EPA)	DTXSID50912008 ;
ECHA InfoCard	100.014.306
Chemical and physical data
Formula	C33H57N3O9
Molar mass	639.831 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	125 to 129 °C (257 to 264 °F)
	SMILES CC(C)[C@H]1C(=O)OC(C(=O)N([C@H](C(=O)OC(C(=O)N([C@H](C(=O)OC(C(=O)N1C)C(C)C)C(C)C)C)C(C)C)C(C)C)C)C(C)C;
	(what is this?) (verify)

Fusafungine (INN), also known as fusafungin, is an active agent used in antibiotics for treatment of nasal and throat infection. It also possesses anti-inflammatory properties. Fusafungine is a mixture of enniatin cyclohexadepsipeptides made up of alternating D-α-hydroxyvaleric acid and L-N-methylamino acid residues,^[1] produced by the ascomycete Fusarium lateritium, and marketed by Servier under the trade names Locabiotal, Bioparox, and Locabiosol.

According to a pooled analysis study done in the UK for the efficacy of fusafungine in rhinopharingitis, it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo.^[2]

In February 2016, the European Medicines Agency recommended the withdrawal of fusafungine from the market due to rare but severe allergic reactions (mainly bronchospasms).^[3]

References

^ Levy D, Bluzat A, Seigneuret M, Rigaud JL (December 1995). "Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins". Biochemical Pharmacology. 50 (12): 2105–7. doi:10.1016/0006-2952(95)02045-4. PMID 8849339.
^ Lund VJ, Grouin JM, Eccles R, Bouter C, Chabolle F (December 2004). "Efficacy of fusafungine in acute rhinopharyngitis: a pooled analysis". Rhinology. 42 (4): 207–12. PMID 15626253.
^ "CMDh endorses revocation of authorisations for fusafungine sprays used to treat airway infections". European Medicines Agency. 17 September 2018. Archived from the original on 20 June 2018. Retrieved 18 February 2022.

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

[1] Levy D, Bluzat A, Seigneuret M, Rigaud JL (December 1995). "Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins". Biochemical Pharmacology. 50 (12): 2105–7. doi:10.1016/0006-2952(95)02045-4. PMID 8849339.

[2] Lund VJ, Grouin JM, Eccles R, Bouter C, Chabolle F (December 2004). "Efficacy of fusafungine in acute rhinopharyngitis: a pooled analysis". Rhinology. 42 (4): 207–12. PMID 15626253.

[3] "CMDh endorses revocation of authorisations for fusafungine sprays used to treat airway infections". European Medicines Agency. 17 September 2018. Archived from the original on 20 June 2018. Retrieved 18 February 2022.

[1]

[2]

[3]

v t e Throat preparations (R02)
Antiseptics	Acriflavinium chloride Ambazone Amylmetacresol Benzalkonium Benzethonium Cetrimonium (bromide/chloride) Cetylpyridinium Chlorhexidine Chlorquinaldol Dequalinium Dichlorobenzyl alcohol Hexamidine Hexetidine Hexylresorcinol Myristyl-benzalkonium Oxyquinoline Phenol Povidone-iodine
Antibiotics	Bacitracin Fusafungine Gramicidin Neomycin Tyrothricin
Local anesthetics	Benzocaine Cocaine Dyclonine Lidocaine
Other	Flurbiprofen